Pancreatic Cancer

PANCREATIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Vitamin D and Pancreatic Cancer: is There a Link?

Vitamin D is a biomarker of interest in the pancreatic cancer setting.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends

The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Reliability of Laboratory-Developed Tests Called Into Question

A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials

Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.

PANCREATIC CANCER NEWS

Contrast-Enhanced vs Conventional Endoscopic Ultrasound for Diagnosis of Pancreatic Lesions

February 25, 2021

Pegilodecakin Plus FOLFOX Fails to Improve Outcomes in Metastatic PDAC

February 23, 2021

Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic c

PERT Shows Promise in Unresected Pancreatic Cancer

January 27, 2021

Researchers showed that survival in pancreatic cancer may be influenced by the tumor microbiome and that tumor growth can be influenced via fecal transplantation.

CD73 Inhibitor-Based Triplet Induces Responses in Metastatic PDAC

January 20, 2021

New, less aggressive guidelines have been developed for management of pancreatic cysts.

Neoadjuvant Urelumab Plus Nivolumab and GVAX for Reresected Pancreatic Cancer

November 14, 2020

Next post in Pancreatic Cancer

Pegilodecakin Plus FOLFOX Fails to Improve Outcomes in Metastatic PDAC